ReviewBiosensors2026
The Evolution of Next-Generation Glucose Monitoring Systems: Developments from Conventional Diagnostics to Wearable and Continuous Sensing Platforms-A Narrative Review.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
For the diagnosis of diabetes, glycemic control, treatment modification, and the avoidance of both acute and long-term consequences, accurate glucose monitoring is crucial. This study examines the development of glucose-monitoring systems, from traditional diagnostic tests and finger-prick electrochemical glucometers to wearable, continuous, minimally invasive, and non-invasive sensing platforms. Major invasive technologies, including enzymatic and non-enzymatic electrochemical sensors, microdialysis systems, hexokinase-based photometric assays, and field-effect transistor biosensors, are critically evaluated. The ability of minimally invasive methods to access interstitial fluid with less pain is discussed, including fluorescence probes, surface-enhanced Raman spectroscopy, and microneedle arrays. Emerging non-invasive approaches are also evaluated. These include reverse iontophoresis, optical coherence tomography, infrared and photoacoustic spectroscopy, microwave resonators, smart contact lenses, and AI-assisted wearable systems. Finally, the review identifies major barriers related to sensitivity, selectivity, calibration, biofouling, biocompatibility, physiological variability, and clinical translation. It also outlines opportunities for intelligent, painless, and patient-centered glucose monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.